<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02201017</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-1194-IG-CTIL</org_study_id>
    <nct_id>NCT02201017</nct_id>
  </id_info>
  <brief_title>HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia</brief_title>
  <official_title>HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 621 consecutive male and female subjects, without established CAD, referred to&#xD;
      exercise stress testing (EST) due to 1) chest pain syndromes or equivocal/equivalent angina&#xD;
      with intermediate pretest probability for CAD; 2) , or asymptomatic subjects with diabetes&#xD;
      mellitus who are referred EST for risk assessment prior to initiation of an exercise program.&#xD;
&#xD;
      To validate the diagnostic performance of the HeartTrends device for the detection and ruling&#xD;
      out of myocardial ischemia in a population of subjects who are currently referred for&#xD;
      cardiovascular evaluation using EST.&#xD;
&#xD;
      Prospective multicenter single-armed study, assessing the diagnostic accuracy of HRV analysis&#xD;
      by the HeartTrends device for the detection of myocardial ischemia, as determined by stress&#xD;
      echocardiography.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive percent agreement</measure>
    <time_frame>1 year</time_frame>
    <description>Positive percent agreement of ≥70% (with a lower confidence interval of 60%) between a positive HRV HeartTrends test and a positive ESE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>negative percent agreement</measure>
    <time_frame>1 year</time_frame>
    <description>HeartTrends device testing is associated with a negative percent agreement of ≥70% with negative results detected by ESE.&#xD;
≥10% difference between the positive percent agreement of HRV with ESE and the positive percent agreement of EST with ESE.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">621</enrollment>
  <condition>Heart Rate Variability Ischemia Detection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 621 consecutive male and female subjects, without established CAD, referred to&#xD;
        exercise stress testing (EST) due to 1) chest pain syndromes or equivocal/equivalent angina&#xD;
        with intermediate pretest probability for CAD; 2) , or asymptomatic subjects with diabetes&#xD;
        mellitus who are referred EST for risk assessment prior to initiation of an exercise&#xD;
        program.&#xD;
&#xD;
        Pretest probability of CAD will be based on the ACC 2002 guideline update on exercise&#xD;
        stress testing1.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 21&#xD;
&#xD;
          -  No known CAD&#xD;
&#xD;
          -  Referral for EST due to either one of the following two indications:&#xD;
&#xD;
               1. Chest pain syndrome or equivocal angina in subjects with intermediate pretest&#xD;
                  probability of CAD according to the 2002 updated guidelines for exercise stress&#xD;
                  examination.1 (See definition of intermediate pretest probability of CAD in&#xD;
                  Supplementary Appendix Table at the end of this document); or&#xD;
&#xD;
               2. Asymptomatic subjects with diabetes mellitus referred to EST for risk assessment&#xD;
                  prior to initiation of an exercise program.&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Coronary Syndrome&#xD;
&#xD;
          2. Established CAD&#xD;
&#xD;
          3. Atrial fibrillation or flutter&#xD;
&#xD;
          4. Cardiac Pacemaker&#xD;
&#xD;
          5. Clinical diagnosis of heart failure&#xD;
&#xD;
          6. Severe COPD (FEV1&lt; 50% predicted value)&#xD;
&#xD;
          7. Active myocarditis, constrictive pericarditis, any cardiomyopathy, cardiac or systemic&#xD;
             amyloidosis&#xD;
&#xD;
          8. Known drug or alcohol dependence or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results or in the opinion of the investigator&#xD;
             are not suitable to participate;&#xD;
&#xD;
          9. Any illness that might reduce life expectancy to less than 1 year from screening&#xD;
&#xD;
         10. Left bundle branch block (LBBB), significant intra-ventricular conduction delay (IVCD)&#xD;
             or significant (&gt;1mm) ST deviations on baseline ECG&#xD;
&#xD;
         11. Inability to perform an exercise stress test (i.e. orthopedical or neurological&#xD;
             limitations)&#xD;
&#xD;
         12. Any significant valvular disease defined as:&#xD;
&#xD;
        Established valvular regurgitation or stenosis abnormality above moderate severity 13. BMI&#xD;
        &gt;35 kg/m2 14. Recent (&lt; 6 months) history of pulmonary embolism&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Goldenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>THE ISRAELI ASSOCIATION FOR CARDIOVASCULAR TRIALS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilan Goldenberg, prof</last_name>
    <phone>03-5344703</phone>
    <email>Ilan.Goldenberg@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>MN 55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilan Goldenberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba medical center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ilan Goldenberg, MD</last_name>
      <email>Ilan.Goldenberg@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>refael Koperstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 16, 2014</study_first_submitted>
  <study_first_submitted_qc>July 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

